Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.840
+0.010 (0.21%)
At close: Apr 28, 2026, 4:00 PM EDT
4.840
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:43 PM EDT
Myriad Genetics Revenue
In the year 2025, Myriad Genetics had annual revenue of $824.50M, down -1.56%. Myriad Genetics had revenue of $209.80M in the quarter ending December 31, 2025, a decrease of -0.38%.
Revenue (ttm)
$824.50M
Revenue Growth
-1.56%
P/S Ratio
0.56
Revenue / Employee
$305,370
Employees
2,700
Market Cap
457.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 824.50M | -13.10M | -1.56% |
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.50M | 23.96% |
| Dec 31, 2020 | 557.10M | -81.50M | -12.76% |
| Sep 30, 2020 | 638.60M | - | - |
| Jun 30, 2020 | 638.60M | - | - |
| Dec 31, 2019 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | 851.10M | - | - |
| Dec 31, 2018 | 851.10M | 107.40M | 14.44% |
| Jun 30, 2018 | 743.70M | - | - |
| Dec 31, 2017 | 743.70M | 15.00M | 2.06% |
| Jun 30, 2017 | 728.70M | -42.70M | -5.54% |
| Dec 31, 2016 | 771.40M | 30.90M | 4.17% |
| Jun 30, 2016 | 740.50M | - | - |
| Dec 31, 2015 | 740.50M | 17.40M | 2.41% |
| Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
| Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
| Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
| Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
| Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
| Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
| Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
| Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
| Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
| Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
| Jun 30, 2005 | 82.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| FONAR | 106.03M |
| Prenetics Global | 92.39M |
MYGN News
- 3 hours ago - Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 - GlobeNewsWire
- 12 days ago - Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - GlobeNewsWire
- 14 days ago - Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - GlobeNewsWire
- 19 days ago - Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Myriad Genetics Earnings Call Transcript: Q4 2025 - Transcripts